SEC / FDA / FTC Regulatory Watch2026-07-06SEC/FDA/FTC Regulatory Watch — Week of June 30-July 6, 2026This week’s digest covers the SEC’s novel-ETF comment request and IPO data update, FDA cell-therapy approvals and manufacturing-control signals, and FTC actions on AI accuracy, hidden travel-app fees, digital advertising conduct, and earnings-claim marketing.
SEC / FDA / FTC Regulatory Watch2026-06-29SEC/FDA/FTC Regulatory Watch — Week of June 23–29, 2026This week’s digest covers SEC market-structure and enforcement moves, FDA oncology approvals and outbreak updates, and the FTC’s Johnson & Johnson antitrust amicus brief, with next steps for legal, compliance, and market-monitoring teams.
SEC / FDA / FTC Regulatory Watch2026-06-22SEC, FDA and FTC Watch: Swap-market comments, drug access moves, and merger remediesThis week’s regulatory docket centers on two SEC/CFTC swap-market comment projects, FDA access approvals and a warning-letter batch, and FTC merger remedies plus consumer-protection suits. The digest highlights affected companies, near-term compliance steps, and deadline items for June 16-22, 2026.
SEC / FDA / FTC Regulatory Watch2026-06-15SEC/FDA/FTC Regulatory Watch — Week of June 9–15, 2026The SEC proposes to repeal the 20-year-old trade-through rule (Reg NMS Rule 611) and finalizes FDTA joint data standards; three enforcement cases yield a $3.36B stock fraud complaint against Napster Corp. defendants and final judgments totaling $2.9M. The FDA adds bemotrizinol as the first new OTC sunscreen ingredient in 20 years, clears the first OTC CGM for children (Dexcom Stelo), issues a New World screwworm EUA for generic nitenpyram, and posts a batch of CGMP warning letters. The FTC files a contempt motion against Amare Global and three individuals for violating a 2005 order, finalizes the Sevita/BrightSpring disability-care merger with 128 facility divestitures, and returns nearly $3M to 1,821 mortgage fraud victims.
SEC / FDA / FTC Regulatory Watch2026-06-08SEC/FDA/FTC Regulatory Watch — Week of June 2–8, 2026The SEC's new five-year strategic plan puts digital asset rulemaking first; two fraud cases settle while an insider-trading charge drops in healthcare. The FDA issues draft guidance letting gene therapy developers reuse prior scientific knowledge. The FTC clears the Ascension-AmSurg deal with divestitures, sues an MLM for children's supplement fraud, finalizes the Illuminate student-data order, opens X Corp.'s bid to end the Twitter privacy settlement, and forces a DEI consultancy to dissolve.
SEC / FDA / FTC Regulatory Watch2026-06-01SEC/FDA/FTC Regulatory Watch — Week of May 28–June 1, 2026The SEC proposes scrapping its 2024 climate-disclosure mandate and charges a Texas man in a $12.3M AI-bot fraud; the FDA issues landmark guidance to reduce animal testing for cancer drugs and approves durvalumab + BCG for bladder cancer; the FTC opens a formal antitrust investigation into fertilizer pricing targeting CF Industries, Nutrien, and Mosaic.
SEC / FDA / FTC Regulatory Watch2026-05-28SEC/FDA/FTC Regulatory Watch — Week of May 19–27, 2026This week's key regulatory actions: the SEC settles the Adani bribery case and drops its 50-year 'no-deny' settlement policy; the FDA approves the first-ever hepatitis delta treatment and opens BHT/ADA food additive reviews; plus new SEC rule proposals that could end mandatory quarterly reporting.
